20/11/2026, Friday17:04

Menu

EDITION   :

TRTRENENARARFRFRRURUURUR

Notifications

You have no new notificationsHome
Turkish Aerospace Industries CEO Mehmet Demiroglu said Spain plans to purchase 15 additional Hurjet trainer aircraft after signing a deal for 30 of the Turkish-made supersonic jets, with deliveries to the European nation scheduled to begin in 2028.ASELSAN announced that its GOKALP Counter-UAV System successfully destroyed a target drone using a hit-to-kill interceptor during a live demonstration at the company's Ogulbey Technology Base, marking the entry of a fully mobile and cost-effective solution into Türkiye's autonomous air defense portfolio.President Recep Tayyip Erdogan on Friday criticized the existing global order and the United Nations, warning that binding international accords and judicial rulings are increasingly ignored while the UN system lacks legitimacy for failing to reflect the will of the global community.Foreign Minister Hakan Fidan said Thursday that Ankara has finalized preparations to submit the Mecca defense agreement to parliament for approval, stressing that the pact provides for mutual defense and does not authorize attacks or troop deployments to other countries.The Royal Swedish Academy of Sciences on Wednesday awarded the 2026 Nobel Prize in Chemistry to Henri Kagan and Kenso Soai for discoveries explaining how molecular asymmetry essential to life emerges through autocatalysis, resolving a century-old mystery about homochirality with significant implications for drug development.

Roche lung cancer drug divarasib shows survival gain in trial

Yenişafak English AA13:07, 02/07/2026, ThursdayG: Update: 13:08, 02/07/2026, Thursday
AA
File photo

Swiss pharmaceutical giant Roche has reported promising results from a late-stage clinical trial of its experimental lung cancer therapy divarasib. Early data from Phase III testing suggest the treatment may extend overall survival in patients with previously treated non-small cell lung cancer, marking a potential advance in KRAS-targeted therapies.

Roche lung cancer drug divarasib has delivered encouraging results in a pivotal Phase III study, with the Swiss drugmaker reporting improved outcomes for patients suffering from advanced non-small cell lung cancer (NSCLC) after prior treatments. The findings were announced by Roche on Thursday, highlighting progress in targeted cancer therapies for KRAS G12C mutation cases.

Clinical trial results in NSCLC treatment

According to data from the KRAScendo 1 study, patients receiving divarasib experienced longer periods without disease progression compared with those treated using existing standard therapies, including sotorasib and adagrasib. Roche also indicated that early analyses point to a possible improvement in overall survival rates, although full survival datasets will be shared at a later scientific conference.

Safety profile and ongoing studies

The company reported no new safety concerns during the Phase III trial, stating that observed side effects remained manageable and reversible. This supports continued development of the drug, which is being evaluated further in additional late-stage clinical programs.

Expanding clinical research pipeline

Roche is currently advancing two complementary studies: KRAScendo 2, which examines divarasib in combination with pembrolizumab as a first-line treatment, and KRAScendo 3, which investigates its use following surgery and chemo-immunotherapy. These trials aim to determine the drug’s effectiveness across different stages of lung cancer treatment pathways.

The results position divarasib as a potential new option in the evolving field of targeted oncology therapies, particularly for patients with limited alternatives in advanced NSCLC.

Comments

Comments you share on our site are a valuable resource for other users. Please be respectful of different opinions and other users. Avoid using rude, aggressive, derogatory, or discriminatory language.